Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here.

Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show ...

Biogen’s 4 nominations in the Pharma category for its Friedreich’s ataxia work included 3 in the “direct-to-patient ads for products or services” category and one in the “disease ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

Biogen on Monday said the phase 3 study will evaluate the efficacy and safety of felzartamab compared to the immunosuppressive drug tacrolimus in adults with PMN, with a readout expected in 2029.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.

Biogen's PROMINENT study will assess felzartamab's efficacy and safety versus tacrolimus for adults with primary membranous nephropathy.

Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.